Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for extrapulmonary sarcoidosis.

Robert P Baughman1, Elyse E Lower

  • 1Interstitial Lung Disease and Sarcoidosis Clinic, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267-0565, USA. bob.baughman@uc.edu

Seminars in Respiratory and Critical Care Medicine
|August 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging the Gap: The Emerging Role of memory CD8+ T Cells in Fibrotic Interstitial Lung Disease.

American journal of respiratory cell and molecular biology·2026
Same author

Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis.

Respiratory medicine·2026
Same author

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.

The European respiratory journal·2026
Same author

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Chest·2025
Same author

A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.

The Lancet. Respiratory medicine·2025
Same author

WASOG Clinical Trial Endpoint Task Force: Executive Summary.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2025

Treatment for extrapulmonary sarcoidosis varies by organ. While corticosteroids are common, steroid-sparing options like methotrexate and anti-TNF drugs are vital for chronic or refractory cases.

Area of Science:

  • Immunology
  • Pulmonology
  • Dermatology

Background:

  • Extrapulmonary sarcoidosis involves various organs, necessitating tailored treatment approaches.
  • Asymptomatic cases often require no intervention.
  • Topical therapies can manage localized skin and eye manifestations effectively.

Purpose of the Study:

  • To outline current treatment strategies for extrapulmonary sarcoidosis.
  • To discuss the role of corticosteroids and steroid-sparing agents.
  • To explore alternative therapies for refractory cases, including anti-tumor necrosis factor drugs.

Main Methods:

  • Review of existing literature on sarcoidosis treatment protocols.
  • Analysis of therapeutic responses based on organ involvement.

Related Experiment Videos

  • Identification of alternative treatments for corticosteroid-refractory disease.

    • Main Results:

    • Corticosteroids are the first-line systemic therapy.
    • Methotrexate and hydroxychloroquine are effective steroid-sparing alternatives for chronic sarcoidosis.
    • Tumor necrosis factor inhibitors, such as thalidomide and infliximab, show promise for refractory neurologic and cardiac sarcoidosis.

    Conclusions:

    • Treatment must be individualized based on affected organs and disease severity.
    • Steroid-sparing agents and novel therapies like anti-TNF drugs are crucial for managing chronic and refractory extrapulmonary sarcoidosis.